Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Price Target at $19.00

Perspective Therapeutics, Inc. (NYSE:CATX) has been assigned an average recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $19.00.

A number of brokerages have weighed in on CATX. Oppenheimer reiterated an “outperform” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price objective on shares of Perspective Therapeutics in a research note on Friday, June 14th. B. Riley upped their target price on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, April 9th. Finally, Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were purchased at an average price of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 10,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was purchased at an average cost of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jonathan Robert Hunt purchased 2,500 shares of the company’s stock in a transaction on Friday, May 31st. The stock was bought at an average price of $14.00 per share, for a total transaction of $35,000.00. Following the completion of the purchase, the chief financial officer now directly owns 34,171 shares of the company’s stock, valued at $478,394. The disclosure for this purchase can be found here. In the last three months, insiders bought 30,814 shares of company stock valued at $385,487. Insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter worth $314,000. Taylor & Morgan Wealth Management LLC raised its holdings in shares of Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after buying an additional 50,000 shares during the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth about $40,000. ZWJ Investment Counsel Inc. acquired a new position in Perspective Therapeutics in the 1st quarter valued at about $26,000. Finally, RIA Advisory Group LLC raised its stake in Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after acquiring an additional 99,293 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $10.61 on Wednesday. Perspective Therapeutics has a twelve month low of $2.05 and a twelve month high of $19.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The business had revenue of $0.33 million during the quarter. As a group, equities analysts forecast that Perspective Therapeutics will post -1 EPS for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.